ISRCTN31669765 https://doi.org/10.1186/ISRCTN31669765

Phase I trial: Ocular Technology Group International

Submission date 16/03/2026	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 18/03/2026	**Overall study status** Deferred	
Last Edited 18/03/2026	**Condition category** Eye Diseases	

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Principal investigator

Contact name
Prof Michel Guillon

Contact details
66 Buckingham Gate
London
United Kingdom
SW1E 6AU
+44 (0)2072224224
mguillon@otg.co.uk

Type(s)
Public

Contact name
Ms Deborah Moore

Contact details
66 Buckingham Gate
London
United Kingdom
SW1E 6AU

+44 (0)7015665390
dmoore@otg.co.uk

Type(s)
Scientific

Contact name
Prof Michel Guillon

Contact details
OTG LTD
66 Buckingham Gate
London
United Kingdom
SW1E 6AU
+44 (0)2072224224
mguillon@otg.co.uk

Additional identifiers

Integrated Research Application System (IRAS)
363818

Study information

Scientific Title
Phase I trial: Ocular Technology Group International [The full scientific title will be published within 30 months after the end of the trial]

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 21/11/2025, North Scotland Research Ethics Committee 01 (Summerfield House, 2 Eday Road, Aberdeen, AB15 6RE, United Kingdom; Not available; gram.nosres@nhs.scot), ref: 25/NS/0122

Primary study design
Interventional

Allocation
Randomized controlled trial

Masking
Open (masking not used)

Control
Active

Assignment
Crossover

Purpose
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Study type(s)

Health condition(s) or problem(s) studied
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Device

Phase
Phase I

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

Completion date
30/09/2026

Eligibility

Key inclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Healthy volunteers allowed
Yes

Age group
Mixed

Lower age limit
40 Years

Upper age limit
80 Years

Sex
All

Total final enrolment
0

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
20/03/2026

Date of final enrolment
31/07/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Ocular Technology Group International
66 Buckingham Gate
London
England
SW1E 6AU

Sponsor information

Organisation
CooperVision International Limited

Funder(s)

Funder type

Funder Name
CooperVision

Alternative Name(s)
CooperVision, Inc., CooperVision Inc, CooperVision Inc., CooperVision, Inc

Funding Body Type
Government organisation

Funding Body Subtype
For-profit companies (industry)

Location
United States of America

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available